All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

What the FLOW trial shows about Ozempic and kidney disease progression

Review the FLOW trial evidence on Ozempic for chronic kidney disease. Learn how semaglutide 1 mg slows diabetic kidney disease progression by 24 percent.

By FormBlends Editorial Research|Reviewed by FormBlends Medical Team||
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Key Takeaway

See your GLP-1 options in about 2 minutes. Free and private. See my options →

Review the FLOW trial evidence on Ozempic for chronic kidney disease. Learn how semaglutide 1 mg slows diabetic kidney disease progression by 24 percent.

Ozempic for chronic kidney disease is backed by the strongest evidence of any GLP-1 medication for kidney protection, with the FLOW trial demonstrating that semaglutide 1 mg weekly slowed kidney disease progression by 24 percent in patients with type 2 diabetes and CKD, fundamentally changing the treatment space for diabetic nephropathy.

Diabetic kidney disease: why it progresses to dialysis

Diabetic kidney disease (DKD) is the single most common cause of end-stage kidney disease worldwide, responsible for roughly 44 percent of all new dialysis starts in the United States. The progression from early diabetic nephropathy to dialysis typically takes 10 to 20 years, but once established, the decline can accelerate unpredictably.

The pathophysiology of DKD involves multiple interconnected processes. Chronic hyperglycemia damages the glomerular basement membrane and promotes mesangial expansion. Hemodynamic stress from hypertension and hyperfiltration injures the podocytes (specialized cells that form the kidney's filtration barrier). Inflammation driven by NF-kB and other pathways promotes tubular damage and interstitial fibrosis. diabetic kidney disease pathophysiology

Until recently, the treatment options for slowing DKD progression were limited to RAAS blockade (ACE inhibitors or ARBs), strict glucose and blood pressure control, and SGLT2 inhibitors. The FLOW trial has now added semaglutide to this list, creating a triple-pillar approach to kidney protection in diabetic patients.

What the FLOW trial found for kidney outcomes

The FLOW Trial: Full Results

The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly) was published by Perkovic et al. in the New England Journal of Medicine in 2024. It enrolled 3,533 adults with type 2 diabetes and CKD, defined as eGFR 50 to 75 with UACR 300 to 5,000 or eGFR 25 to 50 with UACR 100 to 5,000. Participants received semaglutide 1 mg weekly or placebo on top of standard care including RAAS blockade. For a complete cost breakdown, see our cheapest GLP-1 without insurance.

GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Ozempic for Kidney Disease: hands holding a pen-style injector with blue liquid

The primary composite endpoint (sustained 50 percent or greater decline in eGFR from baseline, onset of eGFR below 15, initiation of dialysis or transplant, or death from renal or cardiovascular causes) was reduced by 24 percent (HR 0.76, 95% CI 0.66-0.88, P=0.0003). The trial's independent data monitoring committee recommended stopping enrollment early because the benefit had crossed the pre-specified efficacy boundary.

Individual components: sustained eGFR decline was reduced by 22 percent, ESKD was reduced by 26 percent, kidney death by 44 percent (though numbers were small), and cardiovascular death by 29 percent.

eGFR Preservation

The annual rate of eGFR decline was 1.16 mL/min/1.73m2 per year slower in the semaglutide group. To put this in perspective, the average patient with DKD loses approximately 3 to 5 mL/min/1.73m2 per year. Slowing this by 1.16 means approximately a 25 to 35 percent reduction in the rate of kidney function loss, which could translate to multiple additional years before dialysis is needed.

Albuminuria Response

UACR decreased by approximately 24 percent relative to placebo over 2 years. Albuminuria reduction is both a marker of treatment response and a direct contributor to kidney preservation, as proteins in the filtrate damage tubular cells and promote fibrosis.

FLOW subgroups: who still benefited from semaglutide

Pre-specified subgroups in FLOW showed consistent benefit regardless of baseline eGFR (above or below 50), baseline UACR (above or below 1,000), HbA1c level, and concomitant SGLT2 inhibitor use. The benefit was maintained in patients already receiving SGLT2 inhibitors (roughly 20 percent of the cohort), suggesting additive kidney protection.

Ways semaglutide may slow kidney damage in FLOW

Ozempic (semaglutide 1 mg) was the exact formulation used in FLOW, making it the most directly evidence-supported option for kidney protection. Its kidney benefits stem from: how Ozempic protects kidneys

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →

Glycemic improvement: Reducing HbA1c by 1.0 to 1.8 percent lowers the glucose burden that drives glomerular basement membrane thickening, mesangial expansion, and AGE-mediated damage throughout the kidney.

Anti-inflammatory effects: Kidney inflammation, measured by tubular injury markers and inflammatory cytokines, was reduced in FLOW participants on semaglutide. CRP decreased by approximately 30 percent, reflecting broad dampening of the inflammatory state that accelerates nephron loss.

Hemodynamic improvement: Blood pressure reduction of 3.4 mmHg systolic provides direct glomerular protection by lowering intraglomerular capillary pressure, the force that pushes proteins through the damaged filtration barrier.

Weight loss and reduced hyperfiltration: Even at the 1 mg diabetes dose, Ozempic produces 4 to 7 kg of weight loss, which can reduce obesity-related hyperfiltration and renal venous compression.

Direct tubular effects: GLP-1 receptors in the proximal tubule promote sodium excretion and may reduce tubular workload, protecting tubular cells from the energy depletion and injury that drive tubulointerstitial fibrosis.

Safety monitoring for semaglutide in kidney disease

Based on FLOW trial results, semaglutide 1 mg has received or is expected to receive a kidney-related FDA indication. This is a major validation of its kidney-protective role.

Key safety considerations in CKD patients include: monitoring for dehydration during GI side effects (nausea 20 percent, diarrhea 13 percent, vomiting 9 percent at the 1 mg dose), checking serum creatinine within 2 to 4 weeks of starting therapy, and coordinating with existing RAAS blocker and SGLT2 inhibitor dosing to avoid compounded dehydration risk.

Ozempic doesn't require dose adjustment in CKD since it's metabolized by proteolysis. In the FLOW trial, it was safely used in patients with eGFR as low as 25 mL/min/1.73m2. Ozempic dosing in kidney disease

Ozempic carries a boxed warning about thyroid C-cell tumors. It's contraindicated in patients with medullary thyroid carcinoma or MEN2.

Who in the FLOW population may benefit from Ozempic

Based directly on the FLOW trial population, Ozempic for CKD is appropriate for:

  • Adults with type 2 diabetes and CKD stages 2-4 (eGFR 25-75) with albuminuria (UACR 100 or greater)
  • Patients already on improved RAAS blockade who need additional kidney-protective therapy
  • Diabetic CKD patients with high cardiovascular risk, given the 29 percent cardiovascular death reduction seen in FLOW
  • People whose nephrologist wants to maximize kidney protection using all available evidence-based therapies (RAAS blocker + SGLT2 inhibitor + GLP-1 RA)

For non-diabetic patients with CKD or those whose primary need is substantial weight loss, Wegovy (2.4 mg) may be more appropriate, though it lacks a dedicated kidney outcomes trial.

Questions to ask your nephrologist about Ozempic

The FLOW trial gives you and your doctor a clear evidence base. Consider these approaches:

  • Ask your nephrologist directly: "Based on the FLOW trial, should I be on semaglutide for kidney protection?"
  • If you're already on an SGLT2 inhibitor and RAAS blocker, ask about adding Ozempic as a third kidney-protective agent
  • Discuss practical considerations: injection technique, dose titration schedule, and what to do if you experience nausea or vomiting (particularly around hydration)
  • Ask about insurance coverage, as the kidney indication may improve access compared to a diabetes-only rationale

Finding GLP-1 prescriptions for kidney disease

How much does Ozempic slow kidney decline?

In the FLOW trial, semaglutide slowed the annual rate of eGFR loss by approximately 1.16 mL/min/1.73m2 per year. Over 5 years, this could preserve roughly 5 to 6 mL/min/1.73m2 of kidney function compared to standard care alone, potentially delaying dialysis by years.

Can I take Ozempic if I am already on an SGLT2 inhibitor?

Yes. Roughly 20 percent of FLOW trial participants were on SGLT2 inhibitors at baseline, and semaglutide provided additional kidney benefit on top of SGLT2 inhibitor therapy. The combination is increasingly used in clinical practice for maximal kidney protection. Monitor hydration carefully with both medications.

At what stage of CKD should I start Ozempic?

The FLOW trial enrolled patients with eGFR 25 to 75, covering CKD stages 2 through 4. Earlier intervention (stage 2-3) may preserve more kidney function over time, but benefit was demonstrated even at eGFR as low as 25. Discuss timing with your nephrologist based on your specific eGFR trend and albuminuria level.

Ozempic for kidney disease: where the evidence stands

The FLOW trial has cemented Ozempic as a kidney-protective medication for patients with diabetic CKD. Alongside RAAS blockers and SGLT2 inhibitors, it forms part of a powerful triple therapy that addresses multiple pathways of kidney injury simultaneously.

At FormBlends, we help you understand the research that drives your treatment decisions. Talk with your nephrologist about whether Ozempic should be part of your kidney protection plan. GLP-1 medications overview

This article is for informational purposes only and doesn't constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. The information presented here reflects research available as of early 2026 and may not capture the most recent developments.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →
Ozempic for Kidney Disease: What the Research Shows
FormBlends guide cover for Ozempic for Kidney Disease: What the Research Shows.

Research Snapshot

Medication guide
Page type
Medication guide
Page metadata
Page updated
2026-04-01
Page metadata
FormBlends official source
Official source
Ozempic official website
Official source
Retatrutide official website
Official source
Semaglutide official website
Official source
Tirzepatide official website
Official source
Wegovy official website
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Page updated: 2026-04-01.

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Related treatment context

Ozempic for Kidney Disease: What the Research Shows research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use FormBlends tools and data

Compare provider prices, explore local access and check calculations using FormBlends tools and data.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Next Best Reads

GLP-1 Weight Loss

Semaglutide for Chronic Kidney Disease: What the Research Shows

Explore the FLOW trial and other evidence on semaglutide for chronic kidney disease. Learn how this GLP-1 receptor agonist slows kidney decline and reduces cardiovascular risk in CKD patients.

GLP-1 Weight Loss

Tirzepatide for Chronic Kidney Disease: What the Research Shows

Review emerging evidence on tirzepatide for chronic kidney disease. Learn how this dual GLP-1/GIP agonist may protect kidney function through metabolic improvement and anti-inflammatory effects.

GLP-1 Weight Loss

GLP-1 for Chronic Kidney Disease: What the Research Shows

Comprehensive review of GLP-1 medications for chronic kidney disease. Explore how this drug class protects kidneys through hemodynamic, metabolic, and anti-inflammatory mechanisms.

GLP-1 Weight Loss

Wegovy for Chronic Kidney Disease: What the Research Shows

Learn what clinical evidence says about Wegovy for chronic kidney disease. Explore how semaglutide 2.4 mg may benefit kidney health through weight loss and reduced hyperfiltration.

GLP-1 Weight Loss

Zepbound for Chronic Kidney Disease: What the Research Shows

Explore what is known about Zepbound for chronic kidney disease. Learn how tirzepatide's dramatic weight loss and metabolic improvement may protect kidney function, especially in obesity-related CKD.

Retatrutide

Retatrutide for Chronic Kidney Disease: What Research Shows

A research-focused answer to "Retatrutide for Chronic Kidney Disease: What Research Shows". What the evidence can establish, its limits, and retatrutide's investigational status.

Patient Experience

Semaglutide and Chronic Kidney Disease

Semaglutide and Chronic Kidney Disease: patient experience guidance on semaglutide patient experience, with safety context, decision points, and...

Patient Experience

Tirzepatide and Chronic Kidney Disease

Tirzepatide and Chronic Kidney Disease: patient experience guidance on tirzepatide patient experience, with safety context, decision points, and...

Patient Experience

GLP-1 Medications for Kidney Disease: What the Research Shows

GLP-1 Medications for Kidney Disease: What the Research Shows: patient experience guidance on patient experience, with safety context, decision points,...

FormBlends for iPhone

Shot days, doses and progress in one place

The free FormBlends iPhone app tracks GLP-1 doses, shot-day reminders, weight trends, meals and private progress photos.

Free Tools

Calculators to support your weight loss journey.